Participants
| Role | Name | HCID | Charge |
|---|
| Reactant | Morpholine | HCID 8083 | — |
| Reactant | 1-Hydroxybenzotriazole | HCID 75771 | — |
| Reactant | 1,3-Propanediamine, N'-(ethylcarbonimidoyl)-N,N-dimethyl-, monohydrochloride | HCID 2723939 | — |
| Reactant | HCID 23122089 | HCID 23122089 | — |
| Solvent | Dimethylformamide | HCID 6228 | — |
| Product | HCID 23122062 | HCID 23122062 | 51% |
Reaction Steps
N-[(Tetrahydro-3-oxo-1,1-diphenyl-3H-oxazolo[3,4-a]pyrazin-7(1H)-yl)carbonyl]glycine (0.15 g, 0.38 mmol) was dissolved in N,N-dimethylformamide (3 mL). Morpholine (0.14 g, 1.2 mmol), 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.15 g, 0.76 mmol) and 1-hydroxybenzotriazole (0.11 g, 0.77 mmol) were added thereto, and the mixture was stirred at room temperature for 20 hours. To the reaction solution was added ice water, and the mixture was extracted with ethyl acetate. The organic layer was washed with water, an aqueous saturated sodium hydrogen carbonate solution and water and then concentrated under reduced pressure. The residue was purified with silica gel column chromatography (ethyl acetate:methanol=95:5) and powder was formed from hexane to obtain the title compound (90 mg, yield 51%).
Provenance & Evidence
| DOI | 10.6084/m9.figshare.5104873.v1 |
|---|
| Patent number | US07795267B2 |
|---|
| Source dataset | uspto-grants-2010_09 |
|---|
| ORD ID | ord-7d031e4d0edc4da0bf25cc5bfcb2563f |
|---|
| Source note | uspto-grants-2010_09 |
|---|